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Background: The presence of mutation in EGFR gene is known 
as a predictive marker for the response to epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. However, 
whether or not these EGFR mutations are prognostic factors for non–
small-cell lung cancer (NSCLC) is debatable.
Methods: We retrospectively collected a series of samples from 
patients whose EGFR mutation status had been tested, and analyzed 
their survival. The pathologic cell types of 863 patients (520 men, 
343 women) were squamous cell carcinoma in 227, adenocarcinoma 
in 636 patients.
Results: EGFR mutations were detected in 354 patients and it was 
frequently observed in adenocarcinoma in younger, early-stage, 
female never-smokers. In univariate analysis of younger, early-stage, 
never-smoker women, bronchioloalveolar carcinoma pattern and 
the presence of EGFR mutation showed better long-term survival. 
However, in multivariate analysis, age, pathologic stage, and smoking 
status remained significant prognostic factors, whereas EGFR muta-
tion was not. For recurrence, pathologic stage was the only indepen-
dent prognostic factor. After recurrence, smoking status was the only 
significant risk factor that affected postrecurrence survival. However, 
when EGFR TKIs were used in EGFR-mutated patients, survival was 
longer than for those treated with conventional chemotherapy.
Conclusions: Although the EGFR mutation is a predictive marker 
for EGFR TKI response, it is not a prognostic factor in NSCLC. The 
clinical observation that patients with EGFR mutation seem to sur-
vive longer may be because EGFR mutation is more frequently asso-
ciated with other good prognostic factors. Once there is a recurrence, 
administration of EGFR TKI for patients with EGFR mutation may 
increase survival.
Key Words: Genetics, Lung cancer, Biology, Outcomes, Tumor 
markers.
(J Thorac Oncol. 2013;8: 171–178)
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) or anaplastic lymphoma 
kinase (ALK) inhibitors may prolong survival of selected 
patients based on tumor biomakers. For example, erlotinib 
(Tarceva, Astellas Pharma US Inc., NY) demonstrated a 
survival benefit in unselected non–small-cell lung cancer 
(NSCLC) patients who previously failed on conventional che-
motherapy, but one third of the patients in each arm died by 4 
months, and the overall survival advantage was modest.1 Thus, 
identifying the patients who will or will not benefit from the 
EGFR TKIs became crucial for improving patient survival. 
Some of the molecular biomarkers that have been found use-
ful in predicting the clinical outcomes with EGFR TKIs are 
EGFR mutations in the tyrosine kinase domain, and these can 
be detected by DNA sequencing.2,3 Such molecular biomark-
ers can predict the outcomes from EGFR TKI treatment and 
are called predictive markers. However, a prognostic marker 
is different from a predictive marker, as a prognostic marker 
is a patient characteristic or a tumor factor that predicts the 
outcome independent of the treatment administered.
In the study of NSCLC patients treated with 
chemotherapy with or without EGFR TKIs, the patients with 
EGFR mutations fared better than those without mutations, 
irrespective of therapy, which indicates a more indolent 
biological course of the EGFR-mutated tumors.4 Thus, the 
EGFR mutations seem to have a prognostic impact as well. 
As the prognostic role of a marker is important to take into 
account when a marker is studied for its prediction of clinical 
outcome after a given therapy, the prognostic role of the marker 
should be studied as well. One of the best ways to evaluate the 
prognostic impact of a marker is to study the patients who 
underwent surgeries and investigate its role in survival and 
recurrence. Several articles have reported that the presence 
of EGFR gene mutations is a prognostic factor.5–7 However, 
other reports, including our own previous report, showed no 
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difference in overall survival between patients with EGFR-
mutated tumors and those with wild-type.8–11 In most of the 
previous reports, however, the population studied was small 
and thus, may not have been adequate to control confounding 
variables, which may have been related to the EGFR mutation 
and impacted the prognosis.
In this study, we retrospectively investigated the out-
comes of the patients who underwent complete resection for 
NSCLC with reference to EGFR mutational status along with 
other clinical prognostic variables, in an attempt to ascertain 
its impact as a prognostic marker for NSCLC.
MATERIALS AND METHODS
Between June 1998 and February 2010, a total of 2440 
patients underwent resection for NSCLC at Seoul National 
University Hospital. Among them, 945 patients were tested 
for EGFR mutation. We excluded patients with macroscopic 
or microscopic residual tumors after surgery and those with 
small-cell carcinoma, large-cell neuroendocrine carcinoma, 
carcinoids, and other rare pathologic cell types. The final 
cohort consisted of 863 patients. Preoperative, intraoperative, 
and postoperative clinical records were reviewed. The routine 
recording of patient history, findings on physical examination, 
and results of chest roentgenography was done every 3 months 
in the first 2 years postoperatively, and twice a year thereaf-
ter. Contrast-enhanced chest computed tomography (CT) 
was done every 6 months for 2 years, then a low-dose chest 
CT was done twice a year thereafter. An annual examination 
with positron emission tomography–CT was done simultane-
ously with chest CT. Conventional adjuvant chemotherapy 
was recommended for patients with pathologic stage IIa or 
above. The recurrences were treated based on their pattern, 
which included surgery, radiation, chemotherapy, or a com-
bination. The EGFR TKIs were recommended as the second-
line palliative treatment. Final outcome was recorded at either 
the time of death or recurrence. Patients who had not visited 
the clinic were contacted by telephone. Recommendations of 
the Declaration of Helsinki for biomedical research involv-
ing human subjects were also followed. Before January 2005, 
written informed consent for molecular analysis of surgi-
cal specimen was exempted. Written informed consent was 
obtained from individual patients thereafter, and the study 
protocol as well as ethical issues were reviewed and approved 
by Seoul National University Hospital Institutional Review 
Board (H-1012-130-346/C-1111-102-387).
DNA was extracted from five 10-μm-thick paraffin 
sections, containing a representative portion of tumor tissue. 
DNA extraction from formalin-fixed paraffin-embedded tissue 
was carried out, using GentraPuregene DNA purification kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s pro-
tocol. Fifty nanograms of DNA were amplified in a 20-μl reac-
tion solution containing 10 μl of 2× concentrated HotStarTaq 
Master Mix (Qiagen), including polymerase chain reaction 
(PCR) buffer, 3 mM MgCl2, 400 μM each of deoxyribonucle-
otide triphosphate (dNTP), and 0.3 μM each of primer pairs 
(exon 18F:5′-TCCAAATGAGCTGGCAAGTG-3′, 18R:5 
′-TCCAAATGAGCTGGCAAGTG-3 ′; exon 19F:5′-GCAATA 
TCAGCCTTAGGTGCGGCT-3′, 19R:5 ′-CATAGAAAGTGA 
ACATTTAGGATGTG-3 ′; exon 20F:5 ′-CCATGAGTACGT 
ATTTTGAAACTC-3′, 20R:5′-CATATCCCCATGGCAAAC 
TCTTGC-3′; exon 21F:5′-GCTCAGAGCCTGGCATGAA-3′, 
21R:5 ′-CATCCTCCCCTGCATGTGT-3 ′). Of the first PCR 
product, 1 μl was proceeded for the nested PCR using 
each of primer pairs (exon 18F:5′-TGGCAAGTGCCG 
TGTCCTGGCA-3′, 18R:5′-CTCAGTGAAACAAAGAGTA 
AAGTAG-3′; exon 19F:5′-CCTTAGGTGCGGCTCCACA 
GC-3′, 19R:5′-CATTTAGGATGTGGAGATGAGC-3 ′; exon 
20F:5′-GAAACTCAACATCGCATTCATGC-3′, 20R:5′-GCA 
AACTCTTGCTATCCCAGGAG-3′; exon 21F:5′-CTGGCA 
TGAACATGACCCTG-3′, 21R:5′-TGCATGTGTTAAACA 
ATACAGC-3′). Amplifications of EGFR (exon 18–21) were 
performed using a 10 minute (min) initial denaturation at 94°C 
followed by 25 cycles of 60 seconds (s) at 94°C, 60 s at 55°C, 
and 60 s at 72°C, and a 10-min final extension at 72°C. PCR 
products were then purified using a 2% gel with a QIAgen 
gel extraction kit (Qiagen). Nucleic acid (NA) templates were 
processed for the DNA sequencing reaction using the ABI-
PRISM BigDye Terminator version 3.1 (Applied Biosystems, 
Foster, CA) with both forward and reverse sequence-specific 
primers. Twenty nanograms of purified PCR products were 
used in a 10-μl sequencing reaction solution containing 1 μl 
of BigDye Terminator version 3.1 and 0.1 μM of the same 
PCR primer. Sequencing reactions were performed using 
25 cycles of 10 s at 96°C, 5 s at 50°C, and 4 min at 60°C; 
sequence data were generated with the ABI-PRISM 3100 
DNA Analyzer (Applied Biosystems), and sequences were 
analyzed by Sequencing Analysis 5.1.1. software (Applied 
Biosystems) to compare variations.
The relationship between the clinical outcomes (overall 
survival and freedom from recurrence) and mutation status 
of EGFR was analyzed along with clinical variables. For the 
analysis, we selected the following clinical variables that had 
been known to affect long-term survival of NSCLC: sex, age, 
smoking status, tumor, node, metastasis stage (according 
to the 7th edition of American Joint Committee on Cancer 
staging), and microscopic characteristics. Frequency of 
gene mutations was calculated for each category and then 
tested for association by using the χ2 test for each clinical 
factor. Overall survival and recurrence were investigated by 
using the Kaplan–Meier method, and the difference between 
groups determined by risk factors was tested by using the 
log-rank test. Cox’s proportional hazard model was used to 
explore the influence of independent prognostic factors in a 
multivariable model. The factors were chosen by a stepwise-
forward method with criteria for variable inclusion of 0.05 
and for variable exclusion of 0.10. A 5% significance level 
was considered for statistical significance. All analyses were 
performed using IBM SPSS Statistics 19 for Windows (SPSS 
Inc., Chicago, IL).
RESULTS
The clinical characteristics of the 863 patients are 
summarized in the Table 1. The mean age was 63 years 
(range, 27–87). Five hundred and twenty patients were 
men and 343 were women. Pathologic cell types were 
squamous cell (SQ) in 227, adenocarcinoma (AD) in 587, 
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adenosquamous cell (ADSQ) in 19, and bronchioloal-
veolar carcinoma (BAC) in 30 patients. Microscopically, 
324 patients showed bronchioloalveolar cell carcinoma com-
ponents. Four hundred and ninety-three patients (57.1%) 
were stage I, 393 patients (45.9%) were never-smokers, 305 
(35.6%) were exsmokers, and 159 (18.6%) were current 
smokers. In six patients, smoking history was not available. 
Neoadjuvant chemotherapy was administered in 23 patients 
and concurrent neoadjuvant chemoradiation was performed 
in three patients. None of the patients had been treated with 
EGFR TKIs before surgery.
EGFR mutations were detected in 354 patients. The 
most common site of mutation was in exon 19 (exon 18 in 15, 
exon 19 in 169, exon 20 in 23 and exon 21 in 156 patients). 
The correlation between the frequency of EGFR mutation 
and the clinical variables are listed in Table 1. The EGFR 
mutations were frequently observed in younger, early-stage, 
female never-smokers. The pathologic cell types were related 
to the frequency of EGFR mutations. The EGFR mutations 
were detected more frequently in AD, ADSQ carcinoma, or 
BAC, whereas they were not frequent in SQ type (SQ 3.5%; 
AD 54.3%; ADSQ, 57.9%; BAC, 53.3%). We merged AD, 
ADSQ, and BAC as an AD group and used it for further 
analysis.
There were eight cases of operative death. Long-term 
outcome was analyzed for 855 patients, excluding the eight 
operative death cases. During the follow-up period (23.6 ± 0.7 
months), 235 patients (27.5%) experienced recurrences and 
66 patients (28.1%) died of the disease. Among the patients 
who did not recur, 36 patients (4.2%) died of various causes 
not related to their lung cancer. The overall 5-year survival of 
the 855 patients was 72.9 ± 3.7%. The 5-year freedom from 
recurrence rate was 26.9 ± 5.0%.
The overall survival was analyzed based on the clinical 
variables. In univariate analysis, in the younger age, early-
stage, never-smoker women, the presence of BAC components 
and the presence of EGFR mutation showed better long-term 
survival (Table 2, Fig. 1). As there were tight correlations 
between the presence of EGFR mutation and good clini-
cal variables, we performed multivariate analysis to correct 
hidden confounding effects. In Cox’s proportional hazard 
model, age, pathologic stage, and smoking status remained as 
significant prognostic factors, whereas EGFR mutation status 
was not (Table 2). We used the same analysis for AD patients. 
Similar results were observed, and the only difference was that 
the age was not included as a significant variable in the multi-
variate analysis for overall survival (Table 3).
We also analyzed factors associated with the develop-
ment of recurrence. In univariate analysis, earlier pathologic 
stage (p = 0.000) and the presence of BAC pattern (p = 0.008) 
showed better outcome in terms of recurrence. The presence 
of EGFR mutation was not related to the occurrence of recur-
rence. In multivariate analysis, pathologic stage (p = 0.000) 
remained the only independent factor that affected recurrence 
(Table 4). The results were the same when we analyzed the 
patients with AD (Table 5).
As there was no difference in the development of 
recurrence according to the EGFR mutation status, we 
suspected that the survival difference was a result of a 
difference in postrecurrence survival and subsequently, 
analyzed 235 patients who recurred. The female (p = 0.021) 
never-smoker (p = 0.009) survived longer after recurrence. 
The cell type (p = 0.485), BAC pattern (p = 0.149), and 
pathologic stage (p = 0.300) were not significant. Although 
TABLE 1. Clinical features and their relationship with EGFR 
mutation in All patients
Features EGFR Mutation
Absent Present p
Sex 0.000
 Male 379 (72.9%) 141 (27.1%)
 Female 130 (37.9%) 213 (62.1%)
 Age, yrs 63.9 ± 9.7 61.8 ± 9.7 0.002
Smoking 0.000
 Never 149 (37.9%) 244 (62.1%)
 Ever 356 (76.7%) 108 (23.3%)
Cell type 0.000
 Squamous 219 (96.5%) 8 (3.5%)
 Adenocarcinoma 290 (45.6%) 346 (54.4%)
BAC pattern 0.000
 Absent 403 (74.8%) 136 (25.2%)
 Present 106 (32.7%) 218 (67.8%)
Pathologic stage 0.000
 I 266 (54.0%) 227 (46.0%)
 I 105 (75.5%) 34 (24.5%)
 III 114 (60.3%) 75 (39.7%)
 IV 24 (57.1%) 18 (17.2%)
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor.
TABLE 2.  Univariate and Multivariate Analyses for Overall 
Survival in all Patients
Variables Univariate 
Analysisa
Multivariate Analysisb
p Hazard Ratio (CI) p
Sex (female) 0.000
Age yrs 0.005 1.037 (1.014–1.061) 0.002
Smoking (never) 0.000 2.374 (1.496–3.769) 0.000
Cell type (adenocarcinoma) 0.000
BAC pattern (present) 0.000
Pathologic stage (I) 0.000 0.000
 II 2.389 (1.340–4.259) 0.003
 III 3.299 (1.964–5.541) 0.000
 IV 6.374 (3.040–13.366) 0.000
EGFR mutation (present) 0.001
 exon 18 0.562
 exon 19 0.037
 exon 20 0.443
 exon 21 0.006
aKaplan–Meier’s survival analysis with log-rank test.
bCox’s proportional hazard model.
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; 
CI, confidence interval.
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there was a tendency of better survival in the EGFR mutation 
group (p = 0.061), it did not reach statistical significance 
(Fig. 2). In multivariate analysis, smoking status (p = 0.008, 
hazard ratio=2.152 [1.223–3.788]) remained the only factor 
that affected postrecurrence survival. Among the 235 recurred 
patients, 97 patients were harboring EGFR mutations. In the 
EGFR mutation group (97), 56 patients were treated with EGFR 
TKIs as a second-line treatment after failure of conventional 
chemotherapy, 10 patients were treated with conventional 
chemotherapy, one patient with crizotinib, (another kind of 
target agent and an ALK inhibitor), and the remaining 30 
patients did not receive systemic chemotherapy and were 
treated with either local modality or supportive care. In wild-
type EGFR group (138), 30 received EGFR TKIs, 49 received 
conventional chemotherapeutic agents, and 59 received local 
or best supportive care. We stratified the recurred patients 
based on the EGFR mutation status and tested postrecurrence 
survival with regard to the systemic treatment given. In 
wild-type EGFR group, there was no difference in each 
treatment modality. However, in the EGFR mutation group, 
the survival was different (p = 0.020) and patients who were 
treated with EGFR TKI had the best survival rate, followed 
by the local treatment or best supportive care group. Patients 
who were treated with conventional chemotherapy showed a 
poor prognosis (Fig. 3). The difference between EGFR TKI 
and conventional chemotherapy groups was statistically 
significant (p = 0.001).
DISCUSSION
A prognostic marker is a patient characteristic or a tumor 
factor that predicts the outcome independent of treatment 
administered, and a predictive marker is a clinical or molecular 
TABLE 3.  Univariate and Multivariate Analyses for Overall 
Survival in Patients with Adenocarcinoma
Variables
Univariate 
Analysisa Multivariate Analysisb
p Hazard Ratio (CI) p
Sex (female) 0.005
Age yrs 0.331
Smoking (never) 0.002 2.482 (1.451–4.244) 0.001
BAC pattern (present) 0.002
Pathologic stage (I) 0.000 0.001
 II 1.326 (0.574–3.065) 0.509
 III 2.309 (1.248–4.273) 0.008
 IV 4.621 (2.005–10.646) 0.000
EGFR mutation (present) 0.012
 exon 18 0.286
 exon 19 0.210
 exon 20 0.194
 exon 21 0.010
aKaplan–Meier’s survival analysis with log-rank test.
bCox’s proportional hazard model.
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; 
CI, confidence interval.
TABLE 4.  Univariate and Multivariate Analyses for Freedom 
from Recurrence in all Patients
Variables Univariate 
Analysisa
 
Multivariate Analysisb
p Hazard Ratio (CI) p
Sex (female) 0.707
Age yrs 0.408
Smoking (never) 0.504
Cell type (adenocarcinoma) 0.951
BAC pattern (present) 0.008
Pathologic Stage (I) 0.000 0.000
 II 2.019 (1.376–2.962) 0.000
 III 2.351 (1.705–3.241) 0.000
 IV 6.549 (4.076–10.523) 0.000
EGFR mutation (present) 0.959
 exon 18 0.308
 exon 19 0.822
 exon 20 0.351
 exon 21 0.880
aKaplan–Meier’s survival analysis with log-rank test.
bCox’s proportional hazard model.
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; 
CI, confidence interval.
FIGURE 1.  Comparison of survival curve after curative  
resection of NSCLC according to the presence of EGFR  
mutations (Kaplan–Meier’s survival curve with log-rank  
test). NSCLC, non–small-cell lung cancer; EGFR, epidermal 
growth factor receptor.
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marker that predicts the outcome of a specific treatment. 
The most typical example is human epidermal growth factor 
receptor 2 in breast cancer, which is an unfavorable prognostic 
marker in the patients treated only with surgery, but a good 
predictive marker for treatment with trastuzumab (Herceptin, 
Roche Ltd., Basel, Switzerland).12 The discovery of specific 
EGFR mutations associated with sensitivity to EGFR TKIs 
was significant and provided new insights into the mechanisms 
of the sensitivity to these drugs.
Although there is consistency in the data show-
ing a strong association between specific EGFR mutations 
and response to EGFR TKIs in advanced NSCLC, the role 
of EGFR mutations as a prognostic marker for survival in 
patients with NSCLC is still not proven. The Iressa NSCLC 
Trial Assessing Combination Treatment (INTACT) study did 
show a significantly increased survival of EGFR mutation-
positive patients treated with chemotherapy, irrespective of 
EGFR TKI.13 These findings are also in agreement with the 
molecular analysis of a phase III trial of erlotinib (Tarceva 
responses in conjunction with paclitaxel and carboplatin 
[TRIBUTE]).4 Others, however, have reported no prognostic 
role.9–11,14 Thus, the role of EGFR mutations as a prognostic 
marker in NSCLC remains controversial. The discrepancies in 
these studies may be because of the existence of confounding 
factors such as different clinical characteristics.
Previously, we reviewed 71 lung AD patients who under-
went surgical resection and analyzed the presence of EGFR 
mutations as a prognostic factor for long-term survival.10 
In that study, we demonstrated that no association existed 
between EGFR mutation and overall survival after we had 
controlled confounding variables. Similar reports have been 
subsequently published by many centers.5,15,16 Compared with 
previous reports, our current series is one of the largest studies 
that tested the value of EGFR mutation in patients after sur-
gery as a prognostic marker. The frequency of EGFR mutation 
in our series was 41%, and if we selected only AD patients, it 
would have been 54.3%. The prevalence of EGFR mutation is 
reported to be higher in East Asians compared with whites.17 
With an increasing number of female, nonsmoking lung cancer 
patients, the frequency of detecting EGFR mutations seems to 
FIGURE 2.  Comparison of survival curve after recurrence 
according to the presence of EGFR mutations (A), Kaplan–
Meier’s survival curve with log-rank test and smoking status 
(B), Cox’s proportional hazard model. EGFR, epidermal 
growth factor receptor.
TABLE 5.  Univariate and Multivariate Analyses for Freedom 
from Recurrence in the Patients with Adenocarcinoma
Variables Univariate 
Analysisa
 
Multivariate Analysisb
p Hazard Ratio (CI) p
Sex (female) 0.540
Age yrs 0.529
Smoking (never) 0.244
BAC pattern (present) 0.002
Pathologic stage (I) 0.000 0.000
 II 2.333 (1.462–3.723) 0.000
 III 2.488 (1.736–3.565) 0.000
 IV 6.929 (4.164–11.531) 0.000
EGFR mutation (present) 0.810
 exon 18 0.263
 exon 19 0.692
 exon 20 0.392
 exon 21 0.520
aKaplan–Meier’s survival analysis with log-rank test.
bCox’s proportional hazard model.
BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; CI, 
confidence interval.
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be increasing in recent years. It is noteworthy that the frequency 
of EGFR mutations among the patients with AD in our hospital 
during the recent 1-year period was as high as 58.0% (data not 
published). In our previous study, we were not able to find a sta-
tistically significant association between sex and EGFR muta-
tion, and suggested that a larger study population might have 
resulted in statistical significance. In our current study, using a 
larger  number of patients, we could successfully demonstrate 
that EGFR mutation was more prevalent in women than in men. 
Other clinical variables such as age, stage, cell type, smoking 
status, and the presence of BAC pattern were associated with 
EGFR mutation. Such observations coincided with the results 
of others.5 In univariate analysis, the long-term survival was 
better in younger, early-stage, never-smoker women, and also 
when there was a BAC pattern along with the presence of EGFR 
mutations. As these clinical variables are already well-known 
prognostic factors, the good prognostic outcome in patients 
with EGFR mutations may be because of the effect from the 
close linking of these variables to the presence of EGFR muta-
tions (Table 1). Hence, it is not easy to investigate the true 
prognostic role of EGFR mutation. To control the confounding 
effects of these clinical prognostic factors, we performed mul-
tivariate analysis using Cox’s proportional hazard model. In the 
final model, age, pathologic stage, and smoking status remained 
the significant prognostic factors for overall survival, whereas 
EGFR mutation status was not. This result suggests that the 
presence of EGFR mutation itself may not be a true prognostic 
factor for long-term survival in NSCLC. Similar results have 
been demonstrated by others.14–16,18
As the NSCLC has heterogenous cell types and the 
EGFR mutation is rarely detected in SQ carcinoma, we per-
formed the same analysis excluding SQ carcinoma. The cor-
relation between clinical variables and the presence of EGFR 
mutations was similar to that of entire cell types except for 
age. However, as the difference of the age in the entire group 
was only 1 year it seemed to have no meaning from a practical 
point of view. Multivariate analysis resulted in similar obser-
vations except for the fact that age was omitted from the final 
model. Only pathologic stage and smoking status remained 
statistically significant variables (Table 3).
Although the current study is based on a large number 
of patients, most of them were in early stage. As a conse-
quence, the number of recurrences and subsequent cancer-
specific mortalities were relatively low. The mean follow-up 
duration of 23.6 months may not be sufficient to come to a 
definite conclusion. However, our result can add the evidence 
that EGFR mutation status alone is not a meaningful prognos-
tic biomarker for early-stage NSCLC.
We analyzed whether or not the EGFR mutation status 
affected the development of recurrence. The presence of EGFR 
mutations was not a significant prognostic factor for either 
disease-free survival (log-rank test p = 0.148) or freedom 
from recurrence (log-rank test p = 0.959, Fig. 4). If the EGFR 
mutation was related to the tumor behavior and happened to be 
a prognostic factor, the recurrence should have been affected 
by the presence of EGFR mutation. Such observations of 
recurrence coincides with the results of Sonobe et al.6 They 
selected 32 KRAS mutation patients and 48 EGFR mutation 
patients and compared the disease-free survival rates. They 
found that disease-free survival was influenced by the mode 
of surgical resection and the pathologic stage of the lung 
cancer. Age, sex, smoking status, and gene mutations were not 
significant. Interestingly, however, only pathologic stage and 
gene mutations were the significant factors for determining 
FIGURE 3.  Comparison of survival curve after recurrence 
according to the presence of EGFR mutations and palliative 
treatment modalities (Kaplan–Meier’s survival curve with 
log-rank test) (A), wild-type EGFR, (B), mutated EGFR.EGFR, 
epidermal growth factor receptor.
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overall and long-term survival. Their finding is different from 
our study, where the patients with EGFR mutations showed 
better overall survival than those without in univariate analysis 
only (Fig. 1). In multivariate analysis, the EGFR mutation was 
no longer a significant prognostic factor (Table 1). The role 
of KRAS mutation as a prognostic marker may explain the 
discrepancy. Their comparison was between EGFR-mutated 
patients, and KRAS-mutated patients, and excluded those with 
both the wild-type. We have previously reported that the KRAS 
mutation was a poor prognostic factor in AD of the lung.10 As 
the KRAS mutation is well known to be a poor prognostic 
marker, their observation of better overall survival in the EGFR 
mutation group could have resulted from a poor overall survival 
of the KRAS mutation group. Unfortunately, the KRAS 
mutations were not tested in our patient cohort and we could 
not prove this issue in this study. They also analyzed survival 
after recurrence, and treatment modality, and suggested that a 
better responsiveness to EGFR TKIs might explain the superior 
survival rate in the EGFR mutation group.6 When we compared 
postrecurrence survival in both the groups, the EGFR mutation 
patients showed a trend for better survival. However, the p value 
did not reach statistical significance (Fig. 2). In multivariate 
analysis, smoking status (p = 0.008, hazard ratio=2.152 [1.223–
3.788]) remained the only factor which affected postrecurrence 
survival and the EGFR mutation was not. We also tested to 
determine whether or not there is any survival benefit of using 
EGFR TKIs for patients with EGFR mutations. We stratified 
recurred patients based on the EGFR mutation status and 
the treatment given. In wild-type EGFR group, there was no 
difference in each treatment modality. By contrast, for those 
with EGFR mutation, the survival was different (p = 0.020), 
and patients who were treated with EGFR TKIs survived 
longer than those treated with conventional chemotherapeutic 
regimens (p = 0.001, Fig. 3). Such observations coincided with 
our current knowledge that EGFR mutation is a predictive 
marker for EGFR TKI treatment.
In conclusion, although the EGFR mutation is a predic-
tive marker for EGFR TKI response, the presence of EGFR 
mutation is not a prognostic factor in NSCLC. The clinical 
observation that patients with EGFR mutation seem to survive 
longer may be because EGFR mutation is more frequently 
associated with other significant prognostic factors, such as 
age, stage, or smoking status. On the basis of our results, the 
pathologic stage seems to affect the prognosis by influenc-
ing the cancer recurrence, and smoking status seems to be 
the most important prognostic factor for overall survival. For 
recurred patients, administration of EGFR TKI for EGFR-
mutated patients may offer improved survival gain over those 
who receive conventional chemotherapy.
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